Display options
Cite
Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021;280:121312doi: 10.1016/j.biomaterials.2021.121312.
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., & Zhang, X. (2021). Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 280121312. https://doi.org/10.1016/j.biomaterials.2021.121312
Yu, Yunjian, et al. "Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy." Biomaterials vol. 280 (2021): 121312. doi: https://doi.org/10.1016/j.biomaterials.2021.121312
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06. PMID: 34896861.
Copy Download .nbib Format: NLM
Share it on

Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06.

Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.

Biomaterials

Yunjian Yu, Jie Li, Boyi Song, Zhuang Ma, Yufei Zhang, Haonan Sun, Xiaosong Wei, Yayun Bai, Xueguang Lu, Peng Zhang, Xinge Zhang

Affiliations

  1. Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, 300071, PR China.
  2. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  3. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; MOE Key Laboratory of Macromolecule Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027, PR China. Electronic address: [email protected].
  4. Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, 300071, PR China. Electronic address: [email protected].

PMID: 34896861 DOI: 10.1016/j.biomaterials.2021.121312

Abstract

Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a series of drawbacks. Herein, an all synthetic nanoparticle with PD-L1 blockade capability is developed for cancer photothermal-immunotherapy. The polymeric nanoparticle integrates photothermal treatment, antitumor vaccination, and PD-1/PD-L1 blockade in a single system to augment the antitumor efficacy. In a CT26 bilateral tumor model, intravenously injected nanoparticles accumulate in tumor sites and mediate strong photothermal effects, eradicate the NIR treated primary tumors and elicit strong antitumor immunity by inducing immunogenic cell death (ICD). Growth of the untreated distant tumors is also suppressed due to the synergies of systemic antitumor immune activation and PD-L1 blockade. Our strategy offers a simple but promising approach for the treatment of metastatic cancer.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords: Antitumor immunity; Metastatic cancer; PD-L1 blockade; Photothermal treatment; Polymeric nanoparticle

Publication Types